Spinogenix adds Phase IIb autism study to CLARITY basket trial
Clinical Trials Arena
Spinogenix has expanded its CLARITY basket trial by adding a Phase IIb study focused on autism. The trial aims to evaluate the company's investigational therapy, SPN-812, in multiple patient populations with neurodevelopmental disorders. This expansion reflects Spinogenix's commitment to exploring the potential of SPN-812 across a range of conditions.
All articles from 15 October 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.